THRD (Third Harmonic Bio) חוב לטווח קצר להון

Third Harmonic Bio (THRD) is integrating sustainability principles into the development of immunological drugs by reducing toxic emissions and adhering to trial ethics. The biotech business is optimizing center energy costs and laboratory air filtration. The company currently relies on external capital to test allergy treatments, with the metric standing at 0.00. This chart of quotes for the specific debt-to-equity ratio is provided below.

This ratio assesses the company's dependence on short-term borrowed capital relative to its own equity, where a decrease in the indicator minimizes liquidity risks. By analyzing the structure of short-term liabilities relative to capital, an investor can discern the balance between financial stability and investment potential. For Third Harmonic Bio (THRD), this indicator is critical, as excessive debt pressure could limit the funding of clinical trials for the drug THB001.